RxDoctor Payments Data

Burton Scott, MD

Neurology · Durham, NCNPI 1477654374

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $893 of the $1,391 with a category attached, or 64.2%. Sage Therapeutics, LLC accounts for 84.9% of it on its own, with 1 other manufacturer making up the rest.

$1,391in general payments, 2019–2025

Across 14 payments — averaging $99.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sage Therapeutics, LLC$1K
  • Teva Pharmaceuticals USA, Inc.$210
$1,690,264in research payments, 2019–2025

Across 46 payments — averaging $36,745 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Biogen$1.4M
  • Sage Therapeutics, LLC$142K
  • Neurocrine Biosciences, Inc.$63K
  • Biohaven Pharmaceuticals, Inc.$41K
  • Biohaven Pharmaceutical Holding Company Ltd.$25K
  • AbbVie$18K
  • plus $12K from 1 others

What the payments were for

  • Travel & lodging$89364%
  • Food & beverage$28821%
  • Education$21015%

General payments by program year

19
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,391 in reported general payments places this provider in the 55th percentile of 566 neurology providers in North Carolina.

See all neurology providers in North Carolina

Medicare billing

Part B allowed, 2024
$12,285
Medicare patients
41
Services billed
144

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine43$192,437
Tetrabenazine75$61,308
DepakoteDivalproex Sodium12$7,327
Sertraline Hcl96$813
Gabapentin27$651
Clonazepam89$570
Propranolol Hcl19$561
Primidone13$480
Trihexyphenidyl Hcl21$415
Carbidopa-LevodopaCarbidopa/Levodopa19$341
Risperidone31$317
Baclofen24$275
Trazodone Hcl43$266
Pregabalin11$229
Mirtazapine13$159

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$210$192,43743 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 566 neurology providers in North Carolina.

Other neurology in Durham

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →